AA
SION icon

AlphaCentric Advisors’s Sionna Therapeutics SION Stock Holding History

AlphaCentric Advisors’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
4,863
+45
+0.9% +$1.8K 0.18% 152
2026
Q1 		$193K Buy
4,818
+2,098
+77% +$80.1K 0.19% 148
2025
Q4 		$112K Buy
+2,720
New +$103K 0.11% 214

Other funds holding SION

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TPG GP A
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

AlphaCentric Advisors's SION Position: Q2 2026 in Review

AlphaCentric Advisors increased its Sionna Therapeutics (SION) stake by 0.93% in Q2 2026, buying an estimated $1.8K and bringing the position to 4,863 shares worth $214K. The position accounts for 0.18% of the portfolio, ranked #152.

AlphaCentric Advisors first reported a position in SION in Q4 2025 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • AlphaCentric Advisors held 4,863 shares of Sionna Therapeutics worth $214K as of Q2 2026.
  • AlphaCentric Advisors bought 45 Sionna Therapeutics shares in Q2 2026, an estimated $1.8K.
  • Sionna Therapeutics made up 0.18% of AlphaCentric Advisors's portfolio in Q2 2026, its #152 holding.
  • AlphaCentric Advisors first reported a position in Sionna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.